Torray Investment Partners LLC Has $946,000 Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Torray Investment Partners LLC grew its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 11.5% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 11,747 shares of the company’s stock after buying an additional 1,209 shares during the period. Torray Investment Partners LLC’s holdings in Axsome Therapeutics were worth $946,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. EntryPoint Capital LLC acquired a new position in Axsome Therapeutics in the 1st quarter valued at approximately $35,000. Russell Investments Group Ltd. raised its stake in shares of Axsome Therapeutics by 5,550.0% in the first quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock valued at $63,000 after purchasing an additional 777 shares in the last quarter. Covestor Ltd lifted its position in Axsome Therapeutics by 54,750.0% in the first quarter. Covestor Ltd now owns 1,097 shares of the company’s stock worth $88,000 after purchasing an additional 1,095 shares during the period. Janiczek Wealth Management LLC acquired a new stake in Axsome Therapeutics during the first quarter worth $97,000. Finally, Natixis increased its holdings in Axsome Therapeutics by 13.6% in the 1st quarter. Natixis now owns 1,235 shares of the company’s stock valued at $99,000 after buying an additional 148 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Trading Down 0.5 %

AXSM traded down $0.50 during trading on Friday, reaching $93.19. 945,658 shares of the company’s stock were exchanged, compared to its average volume of 669,595. The company’s fifty day moving average price is $85.45 and its 200-day moving average price is $78.80. The company has a debt-to-equity ratio of 1.77, a quick ratio of 2.40 and a current ratio of 2.48. The firm has a market capitalization of $4.43 billion, a PE ratio of -14.71 and a beta of 1.26. Axsome Therapeutics, Inc. has a fifty-two week low of $55.02 and a fifty-two week high of $98.40.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, August 5th. The company reported ($1.24) EPS for the quarter, topping analysts’ consensus estimates of ($1.30) by $0.06. Axsome Therapeutics had a negative return on equity of 117.46% and a negative net margin of 105.85%. The business had revenue of $87.17 million during the quarter, compared to analysts’ expectations of $84.53 million. As a group, equities analysts forecast that Axsome Therapeutics, Inc. will post -4.72 EPS for the current year.

Insider Activity at Axsome Therapeutics

In related news, COO Mark L. Jacobson sold 47,739 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $84.26, for a total transaction of $4,022,488.14. Following the completion of the transaction, the chief operating officer now owns 5,783 shares in the company, valued at $487,275.58. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 22.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

AXSM has been the topic of several recent research reports. UBS Group decreased their target price on shares of Axsome Therapeutics from $107.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $107.00 price objective on shares of Axsome Therapeutics in a report on Friday. StockNews.com cut Axsome Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 14th. Mizuho restated a “buy” rating and set a $106.00 target price on shares of Axsome Therapeutics in a research report on Wednesday, June 12th. Finally, Royal Bank of Canada lowered their price target on Axsome Therapeutics from $131.00 to $130.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $124.57.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.